Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US10894797B2 · kind B2 · utility
3Cited by
140References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2020 |
| Grant date | Jan 19, 2021 |
| Priority date | — |
| Expiry date | Jun 4, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/107
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.